Hwang J M, Fu K K, Phillips T L
Department of Radiation Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1099-111. doi: 10.1016/s0360-3016(98)00164-3.
To review the results and evaluate the prognostic factors in the retreatment of locally recurrent nasopharyngeal carcinoma.
We reviewed the records of 74 patients with locally recurrent nasopharyngeal carcinoma treated at the University of California, San Francisco between 1957 and 1995. The histologic types included squamous cell carcinoma in 6 (8.1%), nonkeratinizing carcinoma in 48 (64.9%), and undifferentiated carcinoma in 20 (27%) cases. The site of recurrence was in the primary in 46 (62.2%), in the neck nodes in 20 (27%), and in both sites in 8 (10.8%) patients. The recurrent disease was Stage I in 10 (13.5%), Stage II in 16 (21.6%), Stage III in 20 (27%), and Stage IV in 28 (37.9%) patients. Thirty-seven (50%) patients developed recurrence within 2 years and 58 (78.4%) within 5 years after initial treatment. Radiotherapeutic techniques used in the retreatment of primary recurrence consisted of external beam radiotherapy (EBRT), intracavitary brachytherapy, heavy-charged particle beam, and gamma knife, alone or in combination. Reirradiation doses ranged from 18 to 108 Gy, with a median dose of 60 Gy. Treatment of recurrent neck nodes consisted of radical neck dissection (RND) +/- intraoperative radiotherapy (IORT), or EBRT +/- hyperthermia, or chemotherapy +/- hyperthermia. Chemotherapy was used in 22 (30%) patients. Median follow-up was 20 months (range: 2 to 308 months).
The 3-, 5-, and 10-year actuarial overall survival following retreatment were 49, 37, 18%, respectively. Thirty-six patients (49%) were free of further local-regional recurrence after retreatment. The 3-, 5-, and 10-year local-regional progression-free rates were 52, 40, and 38%, respectively. On univariate analysis, histologic type (p < 0.0001), interval to recurrence (p = 0.034), and treatment modality for early-stage disease (p = 0.01) were significant prognostic factors for overall survival, with age being marginally significant (p = 0.053). For local-regional progression-free rate, only histology was significant (p = 0.035). On multivariate analysis, age (p = 0.026), histology (p = 0.015), and interval to recurrence (p = 0.030) were significant for overall survival, and only histology (p = 0.002) and presence of complications (p = 0.016) were significant for local-regional progression-free rate. Of the 64 reirradiated patients, late complications were documented in 29 (45%) patients. The late complications were permanent in 21 (33%) and severe in 15 (23%) patients.
Retreatment using radiotherapy alone or in combination with other treatment modalities can achieve long-term local-regional control and survival in a substantial proportion of patients with locally recurrent nasopharyngeal carcinoma. Age, histology, and interval to recurrence were independent prognostic factors for overall survival, but only histology and presence of complications were significant for local-regional progression-free rate.
回顾局部复发性鼻咽癌再治疗的结果并评估预后因素。
我们回顾了1957年至1995年间在加利福尼亚大学旧金山分校接受治疗的74例局部复发性鼻咽癌患者的记录。组织学类型包括鳞状细胞癌6例(8.1%)、非角化癌48例(64.9%)和未分化癌20例(27%)。复发部位在原发灶46例(62.2%)、颈部淋巴结20例(27%)以及两者均有8例(10.8%)。复发疾病处于Ⅰ期10例(13.5%)、Ⅱ期16例(21.6%)、Ⅲ期20例(27%)和Ⅳ期28例(37.9%)。37例(50%)患者在初始治疗后2年内复发,58例(78.4%)在5年内复发。原发灶复发再治疗所采用的放射治疗技术包括外照射放疗(EBRT)、腔内近距离放疗、重带电粒子束和伽玛刀,单独或联合使用。再照射剂量范围为18至108 Gy,中位剂量为60 Gy。复发性颈部淋巴结的治疗包括根治性颈清扫术(RND)±术中放疗(IORT),或EBRT±热疗,或化疗±热疗。22例(30%)患者使用了化疗。中位随访时间为20个月(范围:2至308个月)。
再治疗后3年、5年和10年的精算总生存率分别为49%、37%、18%。36例(49%)患者再治疗后无进一步的局部区域复发。3年、5年和10年的局部区域无进展率分别为52%、40%和38%。单因素分析显示,组织学类型(p<0.0001)、复发间隔时间(p = 0.034)和早期疾病的治疗方式(p = 0.01)是总生存的显著预后因素,年龄为边缘显著(p = 0.053)。对于局部区域无进展率,只有组织学具有显著性(p = 0.035)。多因素分析显示,年龄(p = 0.026)、组织学(p = 0.015)和复发间隔时间(p = 0.030)对总生存有显著意义,而对于局部区域无进展率,只有组织学(p = 0.002)和并发症的存在(p = 0.016)具有显著性。在64例接受再照射的患者中,29例(45%)记录有晚期并发症。晚期并发症中21例(33%)为永久性,15例(23%)为严重并发症。
单独使用放疗或与其他治疗方式联合进行再治疗,可使相当一部分局部复发性鼻咽癌患者获得长期的局部区域控制和生存。年龄、组织学类型和复发间隔时间是总生存的独立预后因素,但对于局部区域无进展率,只有组织学类型和并发症的存在具有显著性。